1. Home
  2. SO vs SNY Comparison

SO vs SNY Comparison

Compare SO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Company (The)

SO

Southern Company (The)

HOLD

Current Price

$85.73

Market Cap

100.1B

Sector

Utilities

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$48.35

Market Cap

119.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SO
SNY
Founded
1946
1994
Country
United States
France
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.1B
119.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SO
SNY
Price
$85.73
$48.35
Analyst Decision
Hold
Buy
Analyst Count
16
5
Target Price
$95.03
$61.50
AVG Volume (30 Days)
6.6M
2.8M
Earning Date
10-30-2025
01-29-2026
Dividend Yield
3.47%
3.32%
EPS Growth
N/A
105.93
EPS
4.02
8.67
Revenue
$28,913,000,000.00
$53,890,648,839.00
Revenue This Year
$9.72
$2.48
Revenue Next Year
$4.77
$6.47
P/E Ratio
$21.20
$10.99
Revenue Growth
9.40
N/A
52 Week Low
$80.46
$44.62
52 Week High
$100.84
$60.12

Technical Indicators

Market Signals
Indicator
SO
SNY
Relative Strength Index (RSI) 37.60 43.39
Support Level $83.80 $46.97
Resistance Level $87.58 $48.41
Average True Range (ATR) 1.44 0.70
MACD 0.20 -0.09
Stochastic Oscillator 24.16 35.55

Price Performance

Historical Comparison
SO
SNY

About SO Southern Company (The)

Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 44 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the US and sells the electricity primarily under long-term contracts.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: